ML071800245: Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
 
(Created page by program invented by StriderTol)
Line 3: Line 3:
| issue date = 06/26/2007
| issue date = 06/26/2007
| title = Areva, Distribution of ANP-10280P, Revision 0, Poolside Postirradiation Examination of MOX Lead Assemblies.
| title = Areva, Distribution of ANP-10280P, Revision 0, Poolside Postirradiation Examination of MOX Lead Assemblies.
| author name = Gardner R L
| author name = Gardner R
| author affiliation = AREVA NP, Inc
| author affiliation = AREVA NP, Inc
| addressee name =  
| addressee name =  
Line 29: Line 29:
: 5. This Document has been made available to the U.S. Nuclear Regulatory Commission in confidence with the request that the information contained in this Document be withheld from public disclosure.
: 5. This Document has been made available to the U.S. Nuclear Regulatory Commission in confidence with the request that the information contained in this Document be withheld from public disclosure.
The request for withholding of proprietary information is made in accordance with 10 CFR 2.390. The information for which withholding from disclosure is requested qualifies under 10 CFR 2.390(a)(4) "Trade secrets and commercial or financial information." 6. The following criteria are customarily applied by AREVA NP to determine whether information should be classified as proprietary: (a) The information reveals details of AREVA NP's research and development plans and programs or their results.(b) Use of the information by a competitor would permit the competitor to significantly reduce its expenditures, in time or resources, to design, produce, or market a similar product or service.(c) The information includes test data or analytical techniques concerning a process, methodology, or component, the application of which results in a competitive advantage for AREVA NP.(d) The information reveals certain distinguishing aspects of a process, methodology, or component, the exclusive use of which provides a competitive advantage for AREVA NP in product optimization or marketability.(e) The information is vital to a competitive advantage held by AREVA NP, would be helpful to competitors to AREVA NP, and would likely cause substantial harm to the competitive position of AREVA NP.The information in the Document is considered proprietary for the reasons set forth in paragraphs 6(b) and 6(c) above.7. In accordance with AREVA NP's policies governing the protection and control of information, proprietary information contained in this Document have been made available, on a limited basis, to others outside AREVA NP only as required and under suitable agreement providing for nondisclosure and limited use of the information.
The request for withholding of proprietary information is made in accordance with 10 CFR 2.390. The information for which withholding from disclosure is requested qualifies under 10 CFR 2.390(a)(4) "Trade secrets and commercial or financial information." 6. The following criteria are customarily applied by AREVA NP to determine whether information should be classified as proprietary: (a) The information reveals details of AREVA NP's research and development plans and programs or their results.(b) Use of the information by a competitor would permit the competitor to significantly reduce its expenditures, in time or resources, to design, produce, or market a similar product or service.(c) The information includes test data or analytical techniques concerning a process, methodology, or component, the application of which results in a competitive advantage for AREVA NP.(d) The information reveals certain distinguishing aspects of a process, methodology, or component, the exclusive use of which provides a competitive advantage for AREVA NP in product optimization or marketability.(e) The information is vital to a competitive advantage held by AREVA NP, would be helpful to competitors to AREVA NP, and would likely cause substantial harm to the competitive position of AREVA NP.The information in the Document is considered proprietary for the reasons set forth in paragraphs 6(b) and 6(c) above.7. In accordance with AREVA NP's policies governing the protection and control of information, proprietary information contained in this Document have been made available, on a limited basis, to others outside AREVA NP only as required and under suitable agreement providing for nondisclosure and limited use of the information.
: 8. AREVA NP policy requires that proprietary information be kept in a secured file or area and distributed on a need-to-know basis.  
: 8. AREVA NP policy requires that proprietary information be kept in a secured file or area and distributed on a need-to-know basis.
: 9. The foregoing statements are true and correct to the best of my knowledge, information, and belief.SUBSCRIBED before me this _____day of JLL.2007.KI'Sherry L. McFaden NOTARY PUBLIC, COMMONWEALTH OF VIRGINIA MY COMMISSION EXPIRES: 10/31/10*}}
: 9. The foregoing statements are true and correct to the best of my knowledge, information, and belief.SUBSCRIBED before me this _____day of JLL.2007.KI'Sherry L. McFaden NOTARY PUBLIC, COMMONWEALTH OF VIRGINIA MY COMMISSION EXPIRES: 10/31/10*}}

Revision as of 22:28, 12 July 2019

Areva, Distribution of ANP-10280P, Revision 0, Poolside Postirradiation Examination of MOX Lead Assemblies.
ML071800245
Person / Time
Site: Catawba, PROJ0728  Duke Energy icon.png
Issue date: 06/26/2007
From: Gardner R
AREVA NP
To:
Document Control Desk, Office of Nuclear Reactor Regulation
References
NRC:07:024
Download: ML071800245 (5)


Text

--7 A AREVA June 26, 2007 NRC:07:024 Sb -(_j Document Control Desk U.S. Nuclear Regulatory Commission Washington, D.C. 20555-0001 Distribution of ANP-10280P, Revision 0, "Poolside Postirradiation Examination of MOX Lead Assemblies" Ref. 1: Letter, James F. Mallay (Framatome ANP) to Document Control Desk (NRC),"Publication of BAW-10238(P)(A), Revision 1, 'MOX Fuel Design Report'," NRC:04:054, September 21, 2004.Paragraph 3.7.1 of the safety evaluation of BAW-10238(P)(A), Revision 1, (Reference 1)discusses the inspection and testing program of the MOX lead test assemblies that were supplied to Duke Energy's Catawba Nuclear Station, Unit 1, for irradiation starting in spring of 2005. The inspection and testing program includes poolside postirradiation examinations that are to be performed between every irradiation cycle of the test assemblies.

The first cycle of irradiation of the test assemblies was completed in the fall of 2006. The test assemblies were examined at poolside after ultrasonic cleaning during the refueling outage.The appearance of the assemblies was normal. Upon evaluation, all characteristics of the test assemblies were found to be within the criteria for reinsertion for a second cycle of irradiation.

Enclosed are CDs which contain proprietary and non-proprietary versions of report ANP-10280P, Revision 0, "Poolside Postirradiation Examination of MOX Lead Assemblies," for information.

This report documents the results of the first cycle of poolside postirradiation examinations.

AREVA NP considers some of the material contained in the enclosed document to be proprietary.

As required by 10 CFR 2.390(b), an affidavit is enclosed to support the withholding of the information from public disclosure.

Sincerely, Ronnie L. Gardner, Manager Site Operations and Regulatory Affairs AREVA NP Inc.Enclosures Too7 AREVA NP INC.An AREVA and Siemens company 3315-A Old Forest Road, P.O. Box 10935, Lynchburg, VA 24506-0935 Tel.: 434 832 3000 -Fax: 434 832 2953 www.areva.corm I Document Control Desk June 26, 2007 cc: P.M. Clifford H. D. Cruz J. F. Stang, Jr.Project 728 NRC:07:024 Page 2 AFFIDAVIT COMMONWEALTH OF VIRGINIA )) ss.CITY OF LYNCHBURG

)1. My name is Gayle F. Elliott. I am Manager, Product Licensing, for AREVA NP Inc. and as such I am authorized to execute this Affidavit.

2., I am familiar with the criteria applied by AREVA NP to determine whether certain AREVA NP information is proprietary.

I am familiar with the policies established by AREVA NP to ensure the proper application of these criteria.3. I am familiar with the AREVA NP information contained in the report ANP-10280P, Revision 0, "Poolside Postirradiation Examination of MOX Lead Assemblies," dated April 2007, and referred to herein as "Document." Information contained in this Document has been classified by AREVA NP as proprietary in accordance with the policies established by AREVA NP for the control and protection of proprietary and confidential information.

4. This Document contains information of a proprietary and confidential nature and is of the type customarily held in confidence by AREVA NP and not made available to the public. Based on my experience, I am aware that other companies regard information of the kind contained in this Document as proprietary and confidential.
5. This Document has been made available to the U.S. Nuclear Regulatory Commission in confidence with the request that the information contained in this Document be withheld from public disclosure.

The request for withholding of proprietary information is made in accordance with 10 CFR 2.390. The information for which withholding from disclosure is requested qualifies under 10 CFR 2.390(a)(4) "Trade secrets and commercial or financial information." 6. The following criteria are customarily applied by AREVA NP to determine whether information should be classified as proprietary: (a) The information reveals details of AREVA NP's research and development plans and programs or their results.(b) Use of the information by a competitor would permit the competitor to significantly reduce its expenditures, in time or resources, to design, produce, or market a similar product or service.(c) The information includes test data or analytical techniques concerning a process, methodology, or component, the application of which results in a competitive advantage for AREVA NP.(d) The information reveals certain distinguishing aspects of a process, methodology, or component, the exclusive use of which provides a competitive advantage for AREVA NP in product optimization or marketability.(e) The information is vital to a competitive advantage held by AREVA NP, would be helpful to competitors to AREVA NP, and would likely cause substantial harm to the competitive position of AREVA NP.The information in the Document is considered proprietary for the reasons set forth in paragraphs 6(b) and 6(c) above.7. In accordance with AREVA NP's policies governing the protection and control of information, proprietary information contained in this Document have been made available, on a limited basis, to others outside AREVA NP only as required and under suitable agreement providing for nondisclosure and limited use of the information.

8. AREVA NP policy requires that proprietary information be kept in a secured file or area and distributed on a need-to-know basis.
9. The foregoing statements are true and correct to the best of my knowledge, information, and belief.SUBSCRIBED before me this _____day of JLL.2007.KI'Sherry L. McFaden NOTARY PUBLIC, COMMONWEALTH OF VIRGINIA MY COMMISSION EXPIRES: 10/31/10*